Robotic Prostatectomy Has Run Its Course with Dr. Arun Menawat

Robotic Prostatectomy Has Run Its Course with Dr. Arun Menawat

April 14, 2026 · 49 min

About this episode

Dr. Arun Menawat discusses the advancements of the TULSA-PRO® system in comparison to robotic prostatectomy and the future of incision-free surgery.

In this episode of The Crux of MedTech, Henry Norton is joined by Dr. Arun Menawat, Chairman and CEO of Profound Medical, the company behind the TULSA-PRO® system, an MRI-guided, incision-free platform that’s directly challenging robotic prostatectomy with head-to-head clinical data. Arun shares the clinical trial results that show step-change improvements in patient outcomes, the commercial lessons from building and exiting Novadaq (acquired by Stryker), and why he believes incision-free surgery isn’t just a product, it’s the next wave. Key Topics: Head-to-head clinical trial data: TULSA-PRO vs. robotic prostatectomy How MRI-guided thermal ultrasound works and why it matters for patient outcomes The Novadaq journey: from fluorescence imaging to a Stryker acquisition Building a KOL strategy for a novel surgical platform Why incision-free surgery is positioned to disrupt the next decade of surgical care Related Insights: Why you can’t sell to surgeons by telling them they need to be better The role of AI in standardising MR imaging for surgical planning Why CMS reimbursement for TULSA now exceeds robotic surgery How different KOL personas early adopters, visionaries, and…

Topics covered

Keywords

More episodes of The Crux of Medtech

Explore listener stats, chart rankings, contacts and more on the The Crux of Medtech podcast page.